Technology Bundle ID
TAB-3554

Nrf2 Inhibitors for the Enhancement of Cancer Chemotherapy and Radiotherapy

Applications
Linked ID
E-023-2013-0
Lead Inventors
Matthew Boxer (NCATS)
Co-Inventors
Anju Singh (Johns Hopkins University)
Fraydoon Rastinejad (Sanford-Burnham Medical Research Institute)
Jason Rohde (NCATS)
Min Shen (NCATS)
Shyam Biswal (Johns Hopkins University)
Ya-Qin Non Zhang (NCATS)
ICs
This technology includes the identification of small molecule inhibitors of nuclear factor erythroid-2 related factor-2 (Nrf2) as therapeutic anticancer agents. Multiple mechanisms lead to frequent dysregulation of Nrf2 activity in cancer cells, which promotes both tumorigenesis and therapeutic resistance. Dysregulated Nrf2-Keap1 pathway is a novel determinant of chemoresistance/radioresistance and inhibition of Nrf2 signaling will enhance the efficacy of chemotherapeutic and radiotherapy. Based on their potency, specificity and tractability, we have selected 3 compounds for bulk synthesis and screening additional analogues. These compounds belonging to three different structural classes showed direct inhibition of DNA binding activity of Nrf2-MAF complex and were validated as specific inhibitors using a Fluorescence Polarization assay. In combination with platinum-based chemotherapy, these compounds significantly enhanced inhibition compared with single agent in clonogenic assay. These 3 compounds have been resynthesized and their activity as Nrf2 inhibitors has been confirmed using the aforementioned assays.
Commercial Applications
Agent to circumvent therapeutic resistance and enhance the efficacy of chemotherapy and radiotherapy in the treatment of cancer.
Competitive Advantages
First-in-class; currently, there are no known direct pharmacological inhibitors of Nrf2.

Request More Info

Licensing Contact: